Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis? - Wikidata - wikimedia - TriplyDB

Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis?

Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis?

http://www.wikidata.org/entity/Q38674583

about

MiR-411 suppressed vein wall fibrosis by downregulating MMP-2 via targeting HIF-1α.Effectiveness and Safety of Anticoagulants for the Treatment of Venous Thromboembolism in Patients With Cancer.

P2860

Q47267587-D2929D83-4AC7-4D5A-B17D-B4CD89560BB4 Q48111369-1CCEE650-7256-458A-8BFC-E470B529F26A

P2860

Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis?

http://www.wikidata.org/entity/Q38674583

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis?

@en

type

label

Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis?

@en

prefLabel

Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis?

@en

P1433

Q38674583-77988946-E35F-49D0-8999-7F22EA32B4A2

P1476

Q38674583-5FD2E9CD-DB3C-4D58-8406-8961BF461565

P2093

Q38674583-2A7F841C-FE6C-4441-9BD5-ABF5E7872772

Q38674583-34529B65-27A1-43A9-9C90-FAE9BBBAD391

Q38674583-361AD757-CCD4-44B9-88C9-2C22EE63AA9B

Q38674583-380E70DE-EEA6-4DDE-97DD-583B025C8E8F

Q38674583-48F0AFD0-3EB2-4085-A53C-0430EA7C237E

Q38674583-48F22645-BB47-4085-88B5-22F3CCEDE36F

Q38674583-6DAE3AF0-2BDC-4EF2-86EC-C59A1FB2B3A9

Q38674583-D44519DB-ED37-432B-B725-80B271026676

Q38674583-D6CE18A1-20E8-48FE-B3C9-D35BF0CD4B3C

P2860

Q38674583-09591E66-5B90-44D2-BFED-5F9EE8A51E07

Q38674583-0C360BF0-6EA0-45A2-BD52-72985D63B007

Q38674583-1416749F-BB63-4DD1-B48D-D8ED17F7C310

Q38674583-1561500F-9CA2-48B0-A533-1A5F9C74920C

Q38674583-32FDC181-7E27-4535-899F-6BCD500DFE3F

Q38674583-3BBA649D-EA3E-4EB3-A53E-68F272A2999A

Q38674583-41667FFB-F61E-4EA7-876B-CF9A0FAEBF1C

Q38674583-5294C6BD-3270-4606-B902-6D2EF8A00EF2

Q38674583-5F28F271-701F-4CE8-8EA0-EAC268BCAA63

Q38674583-6246E98E-A544-4AF6-85E0-32FDD2013902

P304

Q38674583-F8AC03CD-C376-4F11-B738-1619BC43EE11

P31

Q38674583-575DE533-9527-4F04-9199-BF6CCEC87841

P356

Q38674583-B206ECB3-5B28-4E71-A603-C6480C615AEE

P433

Q38674583-534283ED-A68D-4BCC-8C7D-39FD37886CBD

P478

Q38674583-E586F68B-5D07-494F-B6A4-FABF1570D2D1

P577

Q38674583-A45D0AEB-248C-4372-81BB-498B560B1F8D

P698

Q38674583-9C2F3074-8007-47A9-9267-092DEB2F9C5E

P921

Q38674583-09C60C26-C8C1-4C8A-9973-E1C1C3EB87FE

P932

Q38674583-25C386CE-2510-4F7D-B9D2-9A6E31AB9987

P356

JGO.2015.002527

P1433

Journal of global oncology

P1476

Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis?

@en

P2093

Ana Carolina Carvalho Rocha Paterlini

http://www.w3.org/2001/XMLSchema#string

Fernando Sergio Blumm Ferreira

http://www.w3.org/2001/XMLSchema#string

Flávia Dias Xavier

http://www.w3.org/2001/XMLSchema#string

Gustavo Dos Santos Fernandes

http://www.w3.org/2001/XMLSchema#string

Karime Kalil Machado

http://www.w3.org/2001/XMLSchema#string

Karla Teixeira Souza

http://www.w3.org/2001/XMLSchema#string

Luiza Dib Batista Bugiato Faria

http://www.w3.org/2001/XMLSchema#string

Maria Ignez Braghiroli

http://www.w3.org/2001/XMLSchema#string

Paulo Marcelo Gehm Hoff

http://www.w3.org/2001/XMLSchema#string

P2860

Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer

Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data.

International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.

The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.

Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.

Tissue factor, thrombin, and cancer.

Development and validation of a predictive model for chemotherapy-associated thrombosis.

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.

Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies.

Procoagulant mechanisms in tumour cells.

P304

15-22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JGO.2015.002527

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28717737

http://www.w3.org/2001/XMLSchema#string

P921

P932

5493228

http://www.w3.org/2001/XMLSchema#string